Health Technology Assessment (HTA)

Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
Publication

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

1 February 2020

Cost-Effectiveness Thresholds (CETs) are used in a selected number of countries as tool in decision-making on funding and reimbursements for new healthcare technologies.

Henderson et al - Ehthical and economic Issues - Thumbnail 2
Publication

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

1 January 2020

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting…

Insights

25 Years of the Cost Effectiveness Acceptability Curve

30 December 2019

In 1994 Ben van Hout introduced the concept of the cost effectiveness acceptability curve (CEAC). In the 25 years since, the CEAC has become a standard…

News

OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris

18 December 2019

OHE presented at the Global AMR R&D Hub Board of Members Meeting in Paris, on adapting HTA and payment mechanisms to incentivise new drugs to tackle…

News

HTA and Payment Mechanisms for New Drugs to Tackle AMR

23 September 2019

A new OHE Research Paper summarises the findings of a project funded by the Wellcome Trust on innovative HTA methods and contracting for antibiotics. The paper…

News

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

19 August 2019

OHE Lunchtime Seminar with Steve McKenna, 17th September 2019. The seminar will examine conceptual and practical aspects of measuring value in health care.

News

Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK

17 July 2019

This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…

News

OHE Lunchtime Seminar: Health Years in Total (HYT): A New Health Objective Function for Cost-effectiveness Analysis

20 June 2019

OHE Lunchtime Seminar with Anirban Basu, 24th July 2019. The seminar will examine conceptual and theoretic arguments for use of HYT and illustrate their performance.

News

OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting

7 June 2019

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.